The authors point out that HDM2 inhibition is especially valuable for the treatment of MYCN-amplified neuroblastoma cell lines, as these cells show remarkable sensitivity to MDM2 antagonists in vitro [69]. Here, MDM2 is linked to neuroblastoma.